Telehorse SA (“Issuer”) informs that yesterday it received a signed copy of the letter of intent signed by Neuphoria sp. z o.o. with its registered office in Toruń (“Partner”).
Neuphoria is realizing the project of the ‘National Center for Clinical Research, Diagnostics and Therapy of Epilepsy NEUROSPHERA MIŁOMŁYN’, which will be the first multi-specialized center in Poland that will change the face of care for patients with epilepsy.

The Issuer indicates that after changing the name to ‘Cannabis Poland’, it plans to conduct business in the production and sale of pharmaceutical and medical products with a focus on vaporizing products containing cannabinoids made from hemp. Vaporizing products rich in cannabinoids is considered the most effective, effective and economical method of taking cannabinoids.
Cannabinoids are used in anti-inflammatory, analgesic, anxiolytic, antipsychotic and antispasmodic cures. They are used in Alzheimer’s and Parkinson’s diseases, sclerosis, leukemia, diabetes, asthma, epilepsy, spinal cord injuries, migraines, and withdrawal therapies. They help with rheumatic pains, and have antiemetic and appetite stimulating properties, which is essential for people during chemotherapy. They can also be used in the process of rehab while fighting the addiction of smoking and heroin.
Cannabinoids are also used to treat drug-resistant epilepsy.

The cooperation of Cannabis Poland and the Partner provides for the first in Poland and one of the first in the world research and development of new treatments for epilepsy based on vaporization (inhalation) of cannabinoids.

In the signed agreement, the Parties have expressed their will to negotiate terms of cooperation covering all research activities taking into account such areas as research, registers and clinical studies to which the Partner is authorized, taking into account the full organizational and substantive support. The works would concern the impact of devices and medical devices using the cannabinoid vaporization method for treatment and support of the therapeutic process of disease entities associated with epilepsy and drug-resistant epilepsy management.
Research may also apply to other diseases for which there are preliminary indications regarding the use of cannabinoids with the division into products:
a) less than 0.2% THC;
b) above 0.2% THC, if the Partner and/or Cannabis Poland have obtained the appropriate consent from state offices or other authorization authorities.

The agreement has been concluded for a period of three years and may be terminated by either Party with a three-month notice period.

The size of the medical market, based on cannabis, is estimated in 2028 in Poland at EUR 2 billion and at EUR 58 billion throughout Europe.